DIVERTICOLITE LIEVE: SI PUO’ EVITARE L’USO DI ANTIBIOTICI. IL TRIAL MULTICENTRICO “DINAMO” (FREE)

Efficacy and Safety of Nonantibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study) A Multicentre, Randomised, Open-label, Noninferiority Trial Mora-López, Laura et al. Abstract Objective: Mild AD can be treated safely and effectively on an outpatient basis without antibiotics. Summary of Background Data: In recent years, it has shown no benefit of antibiotics in the treatment…

STATO DI SALUTE DELL’ITALIA 2021. DALLA COMUNITA’ EUROPEA (FREE).

State of Health in the EU:  Italia Profilo della Sanità 2021 Punti salienti L’aspettativa di vita in Italia è tra le più alte in Europa, ma nel 2020 si è abbassata, almeno temporaneamente, a causa dei decessi dovuti al COVID-19. Benché il sistema sanitario italiano garantisca generalmente un buon accesso a prestazioni sanitarie di elevata…

LE NUOVE LINEE GUIDA PER LA MALATTIA DA REFLUSSO DALL’AMERICAN COLLEGE OF GASTROENTEROLOGY (FREE)

ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease Katz, Philip O et al. Abstract Gastroesophageal reflux disease (GERD) continues to be among the most common diseases seen by gastroenterologists, surgeons, and primary care physicians. Our understanding of the varied presentations of GERD, enhancements in diagnostic testing, and approach to patient management…

OCCHIO! IPMN (INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS) DEL PANCREAS SI ASSOCIANO A NEOPLASIE EXTRA-PANCREATICHE NEL 27%.UNA META-ANALISI

Association between pancreatic intraductal papillary mucinous neoplasms and extrapancreatic malignancies: A systematic review with meta-analysis Antonio Facciorusso et al. Abstract Background It is unclear whether patients with intraductal papillary mucinous neoplasia harbor a higher risk of developing extrapancreatic malignancies. Aims We performed a pooled estimate of the incidence of extrapancreatic malignancies in patients with intraductal…

RIFAXIMINA E SIMVASTATINA RIDUCONO IL PROFILO METABOLOMICO INFIAMMATORIO DEL CIRROTICO SCOMPENSATO. DAL PROGETTTO LIVERHOPE (FREE)

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis Elisa Pose et al. ABSTRACT Patients with decompensated cirrhosis, particularly those with acute-on-chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with simvastatin and rifaximin on plasma…

RIFAXIMINA RIDUCE LA INFIAMMAZIONE DI PROVENIENZA INTESTINALE ! IL TRIAL “RIFSYS” SUL J. OF HEPATOLOGY (FREE).

Rifaximin-a reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial Vishal C. Patel et al. Highlights   Rifaximin reduced gut-derived systemic inflammation by suppressing oralisation of the gut microbiome.   Rifaximin suppressed mucin-degrading species rich in sialidase, e.g. Streptococcus and Veillonella spp.   Rifaximin promotes an intestinal environment augmenting re-…